As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cpf1 (also known as Cas12a) genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. Source
No articles found.
Optinose is a specialty pharmaceutical company focused on creating and bringing to...
Optinose is a specialty pharmaceutical company ...
Merrimack is a biopharmaceutical company based in Cambridge, Massachusetts that is...
Merrimack is a biopharmaceutical company based ...
Clearside Biomedical, Inc. is a biopharmaceutical company dedicated to developing ...
Clearside Biomedical, Inc. is a biopharmaceutic...
At GlycoMimetics, we are committed to helping to make a difference in the lives of...
At GlycoMimetics, we are committed to helping t...
BrainStorm (NASDAQ:BCLI) is a biotechnology company developing innovative, autolog...
BrainStorm (NASDAQ:BCLI) is a biotechnology com...
LeMaitre Vascular is a leading global innovator, manufacturer and marketer of devi...
LeMaitre Vascular is a leading global innovator...
LogicBio is a Cambridge, MA-based genome editing company focused on delivering the...
LogicBio is a Cambridge, MA-based genome editin...
Join the National Investor Network and get the latest information with your interests in mind.